Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Region – Market Forecast, 2025–2034

The fabry’s disease treatment market size is expected to reach USD 5,321.12 million by 2034, according to a new study by Polaris Market Research. The report “Fabry’s Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Fabry’s disease treatment market focuses on the development and commercialization of therapies designed to manage the clinical manifestations of Fabry disease, a rare X-linked lysosomal storage disorder caused by a deficiency of the α-galactosidase A enzyme. This enzymatic deficit leads to the systemic accumulation of globotriaosylceramide (Gb3), resulting in progressive damage to vital organs such as the kidneys, heart, and nervous system. The market is being propelled by advances in targeted enzyme replacement therapy (ERT) and the growing availability of oral chaperone therapies that aim to stabilize the misfolded enzymes. Rising awareness among healthcare providers and improved diagnostic capabilities are contributing to earlier detection, expanding the eligible treatment population. Strategic investments in rare disease research, including orphan drug development and precision medicine platforms, are fostering innovation and accelerating regulatory approvals. Market participants are increasingly focusing on gene therapy pipelines that offer the potential for durable or curative outcomes, reflecting a key trend toward next-generation modalities.

Improved reimbursement frameworks and collaborative research initiatives between biopharmaceutical companies and academic institutions are creating new opportunities for the development of differentiated treatment solutions. There is also a rising emphasis on developing treatments tailored to late-onset and atypical phenotypes, addressing unmet needs in diverse patient subgroups. Increasing efforts to monitor long-term efficacy and safety through post-marketing surveillance and real-world evidence generation are reinforcing confidence in therapeutic choices. Overall, the market reflects a dynamic landscape marked by high unmet need, significant clinical complexity, and a robust drive toward innovation in both biologic and small-molecule therapies.

Fabry’s Disease Treatment Market Report Highlights

By route of administration, in 2024, the intravenous route segment accounted for the largest share. Intravenous (IV) administration is the primary method for delivering enzyme replacement therapy (ERT) in Fabry disease treatment.

Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment accounted for approximately 60% of the share. ERT involves intravenous infusions of synthetic enzymes such as agalsidase alfa or beta, which help break down Gb3, slowing disease progression and alleviating symptoms such as neuropathic pain, gastrointestinal issues, and organ dysfunction.

In 2024, the Asia Pacific Fabry’s disease treatment market accounted for the largest share due to increasing awareness of rare genetic disorders and the expansion of diagnostic infrastructure in the region.

The Latin America Fabry’s disease treatment market is projected to grow significantly from 2025 to 2034. Healthcare providers, governments, and advocacy groups in LATAM are prioritizing early diagnosis and access to therapies, fueling the regional market expansion.

A few global key players include Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Chiesi Farmaceutici S.p.A.; Idorsia Pharmaceuticals Ltd.; ISU ABXIS Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Protalix Biotherapeutics Inc.; Sangamo Therapeutics, Inc.; Sanofi; and Takeda Pharmaceutical.

Polaris Market Research has segmented the Fabry’s disease treatment market report on the basis of route of administration, therapy, distribution channel, and region:

By Route of Administration Outlook (Revenue, USD Million, 2020–2034)

Intravenous Route

Oral Route

By Therapy Outlook (Revenue, USD Million, 2020–2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel Outlook (Revenue, USD Million, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Regional Outlook (Revenue, USD Million, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of the Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America